Kolon TissueGene, Inc.

Regenxbio Inc. and AbbVie Inc. are developing a one-time gene therapy for wet age-related macular degeneration that if approved, could intensify cost pressures in a category that is already one of

The Korea Exchange has decided to maintain the stock listing of Kolon TissueGene, Inc. , which has resumed trading on the Kosdaq market after the domestic bioventure fulfilled business improvement co

Upcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populat

Upcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populat